Is Editas Medicine Inc (EDIT) Stock at the Top of the Biotechnology Industry?

Editas Medicine Inc (EDIT) is around the middle of the Biotechnology industry according to InvestorsObserver. EDIT received an overall rating of 50, which means that it scores higher than 50 percent of all stocks. Editas Medicine Inc also achieved a score of 64 in the Biotechnology industry, putting it above 64 percent of Biotechnology stocks. Biotechnology is ranked 48 out of the 148 industries.

EDIT has an Overall Score of 50. Find out what this means to you and get the rest of the rankings on EDIT!

See Full EDIT Report

What do These Ratings Mean?

Finding the best stocks can be tricky. It isn’t easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObserver’s tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector. These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

What's Happening With Editas Medicine Inc Stock Today?

Editas Medicine Inc (EDIT) stock is higher by 0.75% while the S&P 500 has fallen -0.14% as of 12:16 PM on Thursday, Nov 30. EDIT is up $0.08 from the previous closing price of $10.61 on volume of 585,058 shares. Over the past year the S&P 500 has risen 11.38% while EDIT is up 0.85%. EDIT lost -$2.71 per share the over the last 12 months. Click Here to get the full Stock Report for Editas Medicine Inc stock.